ストックスクリーナーアプリを入手
38.98
0.54%
-0.21
前日終値:
$39.19
開ける：
$38.9
24時間の取引高:
5.47M
Relative Volume:
1.01
時価総額：
$45.42B
収益：
$17.53B
当期純損益:
$1.58B
株価収益率:
28.97
EPS:
1.3457
ネットキャッシュフロー:
$444.18M
1週間 パフォーマンス:
+5.10%
1か月 パフォーマンス:
+6.56%
6か月 パフォーマンス:
+31.64%
1年 パフォーマンス:
+111.27%
1日の値動き範囲:
$38.66
$39.38
1週間の範囲:
$37.00
$39.70
52週間の値動き範囲:
$18.21
$39.70
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
名前
Teva Pharmaceutical Industries Ltd Adr
セクター
電話
972 (3) 914-8213
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.98 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
18.91 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.28 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.40 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
494.63 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-12-05 | 開始されました | Scotiabank | Sector Outperform |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-05-28 | 開始されました | Truist | Buy |
| 2025-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-07-10 | アップグレード | Argus | Hold → Buy |
| 2024-03-08 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | アップグレード | Jefferies | Hold → Buy |
| 2024-01-03 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-11-27 | アップグレード | UBS | Neutral → Buy |
| 2023-07-06 | アップグレード | UBS | Sell → Neutral |
| 2023-05-25 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-18 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-01-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-11-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | UBS | Neutral → Sell |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-08-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-06-14 | 再開されました | UBS | Neutral |
| 2022-05-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-05-04 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-03-25 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | ダウングレード | Argus | Buy → Hold |
| 2021-10-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | ダウングレード | UBS | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 開始されました | Oppenheimer | Perform |
| 2020-08-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 再開されました | Goldman | Neutral |
| 2020-06-01 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-24 | 再開されました | Citigroup | Neutral |
| 2020-04-06 | アップグレード | UBS | Neutral → Buy |
| 2020-02-24 | ダウングレード | Edward Jones | Hold → Sell |
| 2019-11-12 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-10-17 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-08-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 開始されました | Wolfe Research | Peer Perform |
| 2019-07-15 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-07-05 | アップグレード | Argus | Hold → Buy |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-06-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | ダウングレード | UBS | Buy → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2019-03-07 | 再開されました | UBS | Buy |
すべてを表示
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Quote Price and Forecast - CNN
Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research
Teva plans senior notes offering to refinance existing debt By Investing.com - Investing.com Canada
TEVA Stock Price, Quote & Chart - ChartMill
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - TradingView
Teva announces commitment with Trump administration on Medicaid drug pricing By Investing.com - Investing.com South Africa
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - Sahm
Teva Pharma Industries Ltd ADR (TEVA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Teva stock hits 52-week high at 37.84 USD By Investing.com - Investing.com Australia
Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA - sahmcapital.com
Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm
Teva receives FDA priority review for Tourette drug - grafa.com
Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria
TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan
Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria
Teva stock hits 52-week high at 37.35 USD - Investing.com
Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm
Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar
July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm
Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm
Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket - investing.com
Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment - Investing.com
Teva stock leans on its generic drug base. - Ad-hoc-news.de
883035 Forecast — Price Target — Prediction for 2027 - TradingView
TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
大文字化:
|
ボリューム (24 時間):